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Many African countries currently use a sulfadoxine-pyrimethamine combination (SP) or amodiaquine (AQ)
to treat uncomplicated Plasmodium falciparum malaria. Both drugs represent the last inexpensive alternatives
to chloroquine. However, resistant P. falciparum populations are largely reported in Africa, and it is compul-
sory to know the present situation of resistance. The in vivo World Health Organization standard 28-day test
was used to assess the efficacy of AQ and SP to treat uncomplicated falciparum malaria in Gabonese children
under 10 years of age. To document treatment failures, molecular genotyping to distinguish therapeutic
failures from reinfections and drug dosages were undertaken. A total of 118 and 114 children were given AQ
or SP, respectively, and were monitored. SP was more effective than AQ, with 14.0 and 34.7% of therapeutic
failures, respectively. Three days after initiation of treatment, the mean level of monodesethylamodiaquine
(MdAQ) in plasma was 149 ng/ml in children treated with amodiaquine. In those treated with SP, mean levels
of sulfadoxine and pyrimethamine in plasma were 100 g/ml and 212 ng/ml, respectively. Levels of the three
drugs were higher in patients successfully treated with AQ (MdAQ plasma levels) or SP (sulfadoxine and
pyrimethamine plasma levels). Blood concentration higher than breakpoints of 135 ng/ml for MdAQ, 100
g/ml for sulfadoxine, and 175 ng/ml for pyrimethamine were associated with treatment success (odds ratio:
4.5, 9.8, and 11.8, respectively; all P values were <0.009). Genotyping of merozoite surface proteins 1 and 2
demonstrated a mean of 4.0 genotypes per person before treatment. At reappearance of parasitemia, both
recrudescent parasites (represented by common bands in both samples) and newly inoculated parasites
(represented by bands that were absent before treatment) were present in the blood of most (51.1%) children.
Only 3 (6.4%) therapeutic failures were the result not of treatment inefficacy but of new infection. In areas
where levels of drug resistance and complexity of infections are high, drug dosage and parasite genotyping may
be of limited interest in improving the precision of drug efficacy measurement. Their use should be weighted
according to logistical constraints.
The spread of resistance of Plasmodium falciparum to chlo-
roquine has pointed to the necessity for several African coun-
tries to identify alternative drugs as first-line antimalarial treat-
ment, taking into account their activity against local parasite
strains but also their tolerability, ease of administration, and
cost (15, 17). Most African countries have now selected the
combination of sulfadoxine and pyrimethamine (SP) as either
first-line or second-line treatment for nonsevere malaria at-
tacks (31). However, several studies also indicate that amodi-
aquine (AQ) is effective in treating chloroquine-resistant P.
falciparum malaria parasites (10, 23), and recent studies report
high cure rates in Africa (1, 4, 34), despite concerns about the
hematological and hepatological side effects reported during
prophylactic use of this drug (24).
In vivo and in vitro tests have been in use for more than 25
years for assessing the activity of drugs against P. falciparum
(37). However, both tests possess their own drawbacks (3). In
vitro tests reflect the mean susceptibility of the multiple para-
site clonal lines present in an individual and may not be able to
detect minor parasite populations that are resistant to the drug
and that are at the origin of treatment failures. In addition,
these tests circumvent the effects of individuals’ immunity,
which are added to that of the drug to achieve parasite clear-
ance. Several point mutations (7, 16) or gene size polymor-
phisms (36) have been proposed as molecular markers of re-
sistance to various antimalarial agents, but the correlations
between molecular patterns and in vivo and in vitro drug sen-
sitivity still need to be validated before these tests may be used
for public health purposes. In vivo tests are a much more direct
* Corresponding author. Mailing address: IRD UR010, Faculte´ de
Pharmacie, Laboratoire de Parasitologie, 4 Avenue de l’Observatoire,













measurement of treatment efficacy in the target population but
cannot distinguish late parasite recrudescences due to treat-
ment failures from parasite reinfections in areas of malaria
transmission. This is of utmost importance, since treatment
failures usually occur more than 7 days after treatment, at a
time when newly inoculated parasite strains may be present in
the peripheral blood after having terminated their exoerythro-
cytic cycle. Moreover, pharmacokinetics of most antimalarial
drugs are highly variable among patients, and it is important to
differentiate a treatment failure due to parasite resistance or to
poor metabolism, not allowing an efficient level of drug to be
reached in the blood. Chromatography techniques have been
designed that allow an accurate and sensitive determination of
the level of most antimalarial drugs in blood (11, 12, 26).
Molecular techniques, on their side, allow characterization of
the parasite populations present in the blood (33) and there-
fore differentiation between recrudescences and reinfections.
Although these techniques are quite sensitive, they also are
money and time consuming and often require additional blood
sampling that may not be easy to achieve during field studies.
Thus, it is of interest to determine the genuine usefulness of
such techniques in conducting drug sensitivity studies. In order
to assess whether treatment failures observed during a stan-
dard in vivo test were related to treatment efficacy or whether
they were the consequence of poor metabolism of the drug or
of reinfection, we conducted such in vivo testing and measured
the drug level achieved in plasma after administration of treat-
ment. In parallel, we compared the polymorphism of merozo-
ite protein 1 (MSP-1) and MSP-2 genes in the parasite popu-
lation before treatment and at reappearance of parasitemia.
MATERIALS AND METHODS
Study area and population. The study was conducted in Bakoumba, a village
located in southeast Gabon in the Haut-Ogooue´ province, between January and
June 2000. This village of 3,000 inhabitants is surrounded by the equatorial forest
and belongs to an area to which P. falciparum malaria is mesoendemic to
hyperendemic, where parasite transmission is perennial with seasonal variations
according to the rains (13). Children of ages 6 months to less than 10 years,
presenting at the outpatient clinic with nonsevere malaria attack, were enrolled
for a 28-day follow-up study according to World Health Organization (WHO)
protocol (37). Children were enrolled if the following criteria were met: age of
10 years, clinical illness compatible with malaria, presence of fever (axillary
temperature, 37.5°C), P. falciparum parasite density of 2,000 asexual para-
sites/l, hemoglobin rate of 5 g/dl, glycemia of 0.4 g/liter, and without any of
the complications defined by WHO guidelines (38). Children presenting with
coma or neurological signs, circulatory collapse, hyperparasitemia above 5%, or
jaundice were not included, as they were considered to have severe malaria, and
were referred to the hospital’s physician. The study was approved by the Centre
International de Recherches Me´dicales de Franceville ethical committee, and
informed consent was obtained from all parents or guardians.
Treatment and follow-up of children. At enrollment, a medical history was
taken and a clinical examination was made. A finger-prick blood sample was
obtained to measure parasite density, and children were orally given SP (Creat,
Vernouillet, France) or AQ (Camoquin, Parke Davis, Dakar, Senegal) under
supervision. Each treatment regimen was given to children enrolled every other
week, and the dosage regimen was based on the child’s weight: 25 mg of sulfa-
doxine/kg of body weight and 1.25 mg of pyrimethamine/kg as a single dose on
day zero (D0), or 30 mg of AQ/kg given in three equal doses on D0 and days 1
and 2. Treatment was completed with three doses of paracetamol per day (10
mg/kg per day) at D0 and day 1. Each antimalarial dose was given at the hospital,
whereas paracetamol doses were given by parents at home. When a child fulfilled
criteria of early or late clinical failure (see data analysis), the child was given an
additional treatment with AQ or SP, the drug he had not received as initial
treatment, and was referred to hospital’s physician. Children presenting with
parasites in blood at the end of the follow-up were also given an additional
treatment. Parents were asked to bring their child back on days 1, 2, 3, 7, 14, and
28 as well as any other day if the child was unwell. Temperature and parasite
density were measured at each visit. Hemoglobin and glycemia rates were eval-
uated on D0 and the following days if values were, respectively, less than 8 g/dl
and 0.6 g/liter at D0. Following finger-prick puncture, 3 drops of blood were
collected on filter paper at D0, days 7, 14, and 28, and any other day if the child
was unwell.
Parasite density, glycemia, and hemoglobin evaluation. All thick blood smears
were Giemsa stained and examined against 500 leukocytes. Parasite densities
were recorded as the number of parasites/microliter of blood, assuming an
average leukocyte count of 8,000/l. All blood smears were examined twice.
Glycemia was measured with a hemoglucotest (Glucotrend; Roche, Mannheim,
Germany). To evaluate hemoglobin rates, blood was collected by finger-prick on
filter paper, and color was compared to a color scale, as described elsewhere (35).
Hemoglobin typing was determined by electrophoresis.
Concentrations of antimalarial drugs in plasma. To determine monodes-
ethyl-AQ (MdAQ), pyrimethamine, sulfadoxine, chloroquine, and quinine con-
centrations, venous blood samples were collected before treatment at D0 and at
day 3 in EDTA tubes. Blood was conserved at 4°C before centrifugation and
plasma separation within 4 h. Plasma was conserved at 20°C before analysis by
high-performance liquid chromatography.
DNA preparation and PCR amplification. After examination of blood smears,
DNA extraction was performed on blood samples from subjects presenting with
a clinical and/or parasitological failure. DNA was prepared from blood collected
at enrollment and on the day when parasites reappeared in blood. Blood col-
lected on Whatmann 3MM filter paper was dried and conserved at room tem-
perature until extraction. DNA was prepared by Chelex extraction, as previously
described (25). Briefly, blood-blotted filter papers were incubated with 1 ml of
0.5% saponin in phosphate-buffered saline (PBS) (pH 7.4) and stored overnight
at 4°C. After microcentrifugation, the PBS-saponin solution was aspirated and
replaced with 1 ml of PBS, and the tubes were incubated for 15 to 30 min at 4°C.
After microcentrifugation, the PBS was aspirated and 100 l of H2O was added
with 50 l of a stock solution of 20% Chelex-100 (Bio-Rad, Richmond, Calif.).
The tubes were heated at 100°C for 10 min in a thermal cycler. After centrifu-
gation at maximal speed for 5 min, supernatants were recovered, centrifuged
again for 10 min, and collected into final tubes. Supernatants were stored at
20°C before being used for PCR.
The oligonucleotide primers were designed from published sequences, as
listed in the nucleotide BLAST database, to amplify the polymorphic regions,
block 2 of MSP-1 (20) and block 3 of MSP-2 (32) (Table 1). The two genes were
amplified by nested PCR, with each amplification with a conserved or family-
specific primer pair being done separately. All reactions were done in a 50-l
final volume, containing 100 mM Tris-HCl, 15 mM MgCl2, 500 mM KCl (pH
8.3), a 200 M concentration (each) of the four dNTPs, a 450 M concentration
(each) of the two appropriate primers, and 2 U of Taq DNA polymerase (Roche,
Mannheim, Germany). In the first reaction, 4 l of Chelex-extracted DNA was
added as a template, and 1 l of the first PCR product was added in the second
reaction. Denaturation at 94°C for 5 min preceded 30 amplification cycles:
denaturation for 2 s at 94°C, annealing for 1 min 30 s at 55°C (first reactions for
MSP-1 and MSP-2) or 58°C (all nested reactions for MSP-1, and the nested
reaction for the MSP-2 3D7 family) or 61°C (the nested reaction for MSP-2 FC27
family), and extension for 2 min at 72°C. The last extension was carried out for
10 min. PCR products were electrophoresed on 1.5% agarose gels in TBE buffer
(100 mM Tris, 100 mM boric acid, and 5 mM EDTA). DNA was visualized by
UV transillumination after staining with ethidium bromide, and fragments ob-
tained were compared by size.
Data analysis. Both clinical and parasitological responses were considered in
analyzing treatment efficacy, according to the revised WHO in vivo protocol for
areas of intense transmission (39) (see Table 2), but the follow-up was extended
to 28 days. This classification differs from the preceding one (37) by the recog-
nition of an additional group (inside the late treatment failures group) of late
parasitological failures defined by the presence of parasitemia on any day be-
tween days 14 and 28, without meeting any of the criteria of early treatment
failure or late clinical failure.
To distinguish true therapeutic failures, with recrudescence of parasites that
were present before treatment administration, from reinfections with blood
proliferation of newly inoculated parasites, the DNA patterns of the parasitized
blood collected on D0 and day of failure (DF) were compared according to
bands’ size and number. D0 and DF patterns were the combination of bands
from the three families of MSP-1 and the two families of MSP-2 within each
blood sample. Bands corresponding to alleles highly common (present in more
than 85% of samples of a given family) were excluded from analysis. True
therapeutic failure was considered when some or all bands observed in the DF











pattern were also present in the D0 pattern, although additional bands may be
present at D0. Reappearance of parasites in blood was considered to be due to
reinfection when some or all bands present in the DF pattern were absent from
the D0 pattern. Consequently, when the DF pattern exhibited both common and
new bands as compared to that of D0, this was considered to involve both a
recrudescence and a reinfection.
Distributions of qualitative data were assessed using a 2 test. Distributions of
qualitative data according to a quantitative variable were analyzed by Kruskal-
Wallis test or Mann-Whitney U test. Dependence of quantitative values was
controlled by correlation. Multivariate analyses were performed by logistic re-
gression. Data were analyzed with the Statview software (SAS Institute Inc.,
Cary, N.C.) and BMDP (Los Angeles, Calif.) statistical software.
RESULTS
Treatment efficacy. A total of 252 patients, less than 10 years
old, were enrolled between January and June 2000. Twenty
children (7.9%) (13 in the SP group and 7 in the AQ group)
were not monitored after day 3 and were excluded from the
analysis. Four children were followed until day 7 (three in the
SP group and one in the AQ group) before being lost there-
after. Consequently, analysis was completed with the clinical
follow-up of 118 children treated with AQ at enrolment and
114 treated with SP combination. The two groups did not differ
in clinical and biological characteristics before treatment (Ta-
ble 3; all P values, 0.10). For the whole group, the mean age
( standard error [SE]) was 3.98 (0.15) years, and 53.8% of
the patients were boys. Overall, 20.3% of the children pre-
sented with the A/S hemoglobin type. On admission, mean
axillary temperature was 38.1°C (0.06), mean glycemia was
0.92 g/liter (0.01), and geometric mean parasite density (95%
confidence interval) was 42,283 (31,313 to 53,254) asexual par-
asites/l of blood. At enrollment, 13 children presented with a
hemoglobin rate between 5 and 7 g/dl; these were controlled
the following days to ensure that normal levels were restored.
Three cases of posttherapeutic pruritus occurred in children
treated with AQ.
Table 4 shows in vivo efficacies of AQ and SP treatments.
AQ was clinically less efficient than SP, with, respectively, 65.3
and 86.0% of adequate clinical and parasitological responses
(ACPR) and 34.7 and 14.0% of therapeutic failures (2 test, P
 0.0002). However, by day 3, parasite clearance occurred
more often and mean temperature was lower, following AQ
treatment (2 test, P  0.003, and Mann Whitney U-test, P 
0.002, respectively). Late parasitological failures (LPF) oc-
curred in 20.3 and 9.6% of children treated with AQ and SP,
respectively, while late clinical failures (LCF) occurred in 13.6
and 2.6%, respectively. If the follow-up had been restricted to
14 days, as in the WHO standard in vivo test, 17 therapeutic
failures would have been detected following AQ treatment,
and 7 would have been detected following SP treatment. In the
AQ group, age favored therapeutic success, since the propor-
tion of adequate clinical response increased with age (Kruskal
Wallis test, P  0.05). In contrast, there was no significant
association between age and treatment outcome following SP
treatment. For the whole group, high parasite densities at
enrollment were related to treatment failure (Kruskal Wallis
test, P  0.004).
TABLE 1. Sequences of oligonucleotide primers used to amplify MSP-1 and MSP-2 polymorphic regions of
P. falciparum isolates from Gabon, 2000
Gene product Primer Sequence Note
MSP-1 MSP1-C1 5	-AAGCTTTAGAAGATGCAGTATTGAC Conserved
MSP1-C2 5	-ATTCATTAATTTCTTCATATCCATC Conserved
K1a 5	-GAAATTACTACAAAAGGTGCAAGTG K1 family specific
K1b 5	-AGATGAAGTATTTGAACGAGGTAAAGTG K1 family specific
MAD20a 5	-AAATGAAGGAACAAGTGGAACAGCTGTTAC MAD20 family specific
MAD20b 5	-ATCTGAAGGATTTGTACGTCTTGAATTACC MAD20 family specific
RO33a 5	-TAAAGGATGGAGCAAATACTCAAGTTGTTG RO33 family specific
RO33b 5	-CATCTGAAGGATTTGCAGCACCTGGAGATC RO33 family specific
MSP-2 MSP2-C1 5	-ATGAAGGTAATTAAAACATTGTCTATTATA Conserved
MSP2-C2 5	-CTTTGTTACCATCGGTACATTCTT Conserved
FC27a 5	-GCAAATGAAGGTTCTAATACTAATAG FC27 family specific
FC27b 5	-GCTTTGGGTCCTTCTTCAGTTGATTC FC27 family specific
3D7a 5	-AGAAGTATGGCAGAAAGTAAGCCTCCTACT 3D7 family specific
3D7b 5	-GATTGTAATTCGGGGGATTCAGTTTGTTCG 3D7 family specific
TABLE 2. Revised WHO classification of treatment failures in
areas of intense malaria transmission
Criterion
Early treatment failure
Development of danger signs or severe malaria on day 1, day 2 or
day 3, in the presence of parasitemia
Parasitemia on day 3 with axillary temperature of 37.5°C
Parasitemia on day 2 higher than day 0 count
Parasitemia on day 3 25% of count on day 0
Late treatment failure
LCF
Development of danger signs or severe malaria after day 3 in
the presence of parasitemia
Presence of parasitemia and axillary temperature 37.5°C on
any day from day 4 to day 28, without previously meeting any
of the criteria of early treatment failure
LPF
Presence of parasitemia on any day from day 14 to day 28, and
axillary temperature 37.5°C, without previously meeting any
of the criteria of early treatment failure or late clinical failure
ACPR
Absence of parasitemia on day 28 irrespective of axillary
temperature without previously meeting any of the criteria of
early treatment failure or late clinical or parasitological failure











Antimalarial concentrations in blood. To assess antimalarial
drug consumption in the target population before treatment,
antimalarial agents were measured at day zero in 44 plasma
samples randomly selected. Four subjects (9.1%) presented
with measurable levels of CQ, monodesethylchloroquine
(MdCQ), AQ, and/or MdAQ (first subject [values in ng/ml]:
CQ, 143, and MdCQ, 46; second subject: MdCQ, 20, AQ, 71,
and MdAQ, 92; third subject: AQ, 422; fourth subject: MdAQ,
50), while traces of MdAQ and/or chloroquine were found in
nine subjects, and traces of quinine were found in four.
To assess posttreatment drug levels, MdAQ, sulfadoxine,
and pyrimethamine were measured in 221 plasmas sampled at
day 3. Mean ( SE) MdAQ, sulfadoxine, and pyrimethamine
plasma concentrations were, respectively, 149.2 (8.2) ng/ml,
100.0 (4.2) g/ml, and 212.0 (14.4) ng/ml. These concen-
trations were positively related to treatment efficacy, as shown
in Fig. 1. In both groups, the proportion of adequate clinical
and parasitological responses was higher for subjects with a
plasma drug concentration above the median (2 test, all P
values  0.04). The probability of having an ACPR according
to plasma concentrations of MdAQ, sulfadoxine, and py-
rimethamine (Table 5) and other covariates which appeared to
be related to ACPR (such as age, parasite density, or glycemia)
was assessed by multivariate analyses. Drug levels in plasma
remained associated with treatment response. Different con-
centration thresholds were then tested in order to determine
for each drug an optimal value of efficacy-to-failure ratio (high-
est estimated odds ratio). These breakpoints were, respec-
tively, 135 ng/ml (MdAQ), 100 g/ml (sulfadoxine), and 175
ng/ml (pyrimethamine).
MSP-1 and MSP-2 genotyping. Of the 54 late treatment
failures observed, DNA was extracted and polymerized from
52 paired samples of subjects, i.e., D0 and DF. Of these 52
pairs of samples, 5 had DF samples that gave no result at the
MSP-1 or MSP-2 locus, and these pairs were subsequently not
analyzed. Before treatment, allelic polymorphism of MSP-1
and MSP-2 loci showed high diversity of P. falciparum isolates,
as 8 different alleles were obtained for MAD20 and 3D7 fam-
ilies, 11 for FC27, 13 for K1, and 3 for the RO33 family.
Forty-seven (90.4%) D0 samples contained parasites belonging
to the K1 family of MSP-1, 33 (63.5%)contained parasites
belonging to the MAD20 family, and 19 (36.5%) contained
parasites belonging to the RO33 family. For MSP-2, 34
(65.4%) isolates sampled contained parasites belonging to the
FC27 family, and 43 (82.7%) contained parasites belonging to
the 3D7 family. Before treatment, the mean number of geno-
types per person (i.e., the mean value of the highest number of
genotypes within any of the two markers) was 4.0.
Table 6 shows the classification of treatment failures with
regard to recrudescence and reinfection. In the whole group of
47 recurrent parasitemia cases analyzed, 44 (93.6%) infections
involved recrudescent parasites (represented by common
bands in both samples), and 27 (57.4%) involved reinfections
(represented by bands that were absent before treatment). The
presence of both recrudescent and newly inoculated parasites
was observed for 24 (53.2%) children, while 20 (42.6%) pre-
TABLE 3. Clinical and biological characteristics of children at enrollment for malaria attack, Bakoumba, Gabon, 2000
Parametera
Value for group
AQ (n  118) SP (n  114)
Age (mean  SE), yr 4.07 (0.2) 3.88 (0.2)
Sex ratio (F/M) 56/62 51/63
Wt (mean  SE), kg 14.2 (0.5) 13.5 (0.5)
Axillary temperature (mean  SE), °C 38.2 (0.08) 38.1 (0.09)
A/S hemoglobin type, % 19.5 21.1
Glycemia (mean  SE), g/liter 0.92 (0.02) 0.92 (0.02)
GMPD (95% CI), per l of blood 46,585 (29,983–63,188) 38,248 (24,001–52,496)
a F, female; M, male; CI, confidence interval; GMPD, geometric mean parasite density.
TABLE 4. In vivo efficacy of AQ and SP treatments of nonsevere P. falciparum malaria attacks in children from southeast Gabon in 2000,




AQ (n  118) SP (n  114)
In vivo treatment response [no. (%) of children]b
ACPR 77 (65.3) 98 (86.0) 0.0002
ETF 1 (0.8) 2 (1.8)
LTFc
LCF 16 (13.6) 3 (2.6)
LPF 24 (20.3) 11 (9.6)
Parasitological clearance by day 3 [no. (%) of children] 97 (82.2) 73 (64.0) 0.003
Mean axillary temperature ( SE) on day 3 36.4 (0.03) 36.6 (0.05) 0.002
a Treatment response is divided into adequate clinical and parasitological response (ACPR), and early (ETF) or late (LTF) treatment failures. According to the
presence or not of clinical symptoms, LTF is divided into LCF or LPF. See Materials and Methods for details.
b One child treated with AQ and 3 treated with SP were monitored only until day 7.
c LTF, late treatment failure.











sented only recrudescent parasites, and 3 (6.4%) presented
only new parasites. Among the 44 recrudescences, 7 occurred
between days 7 and 13, 17 occurred between days 14 and 20,
and 20 occurred between days 21 and 28. All “pure” reinfec-
tions had been treated with AQ and occurred at days 14 (LPF),
20 (LCF), and 21 (LPF).
DISCUSSION
The efficacies of AQ and SP in treating nonsevere malaria
attack in Gabonese children were analyzed according to the
last classification proposed by the WHO (39), which integrates
parasitological failures into late treatment failures. In the pre-
vious WHO classification (37), the reappearance of parasites in
blood in the absence of clinical signs was classified not as a
treatment failure but as an adequate clinical response. How-
ever, the reappearance of parasites in blood could be due to
persistence of parasites that did not respond to treatment.
Our study demonstrates that the SP combination was more
effective than AQ in treating uncomplicated malaria attacks in
children less than 10 years old living in an area of Gabon to
which the disease is highly endemic. Treatment failures with
AQ occurred in 34.7% of children, while only 14.0% showed
treatment failure after SP treatment. With both drugs, most
failures were of the late type. During the present study, the
efficacy of SP was somewhat better than in a previous study
(70%) conducted in 1999 with a smaller group (66 children)
from three different sites (one being Bakoumba) in two prov-
inces of Gabon, all different in size and level of malaria ende-
micity (9). A similar level of resistance to SP was reported in
Cameroon in 1997 and 1999 (30). Indeed, Central Africa
seems to exhibit an intermediate prevalence of resistance to
SP, between East Africa, where the resistance rate is around
30% in Uganda, Kenya, and Tanzania (18, 19, 22), and West
Africa, where the rate of resistance remains lower, in the 0 to
10% range (5, 21). Our study revealed a worsening of the
treatment efficacy of AQ, with more than 30% treatment fail-
ures. Twenty-eight percent resistance was already observed in
Lambarene between 1994 and 1995 (27), and 13% resistance
was observed in Libreville between 1996 and 1998 (6). This
picture is very different from the one from Cameroon, where
no case of resistance occurred in a recent study with adults and
children (30). In East Africa, resistance rates are closer to our
results, with 15 to 25% resistance in Kenya and Tanzania (18).
Field data on pharmacokinetics of AQ, sulfadoxine, or py-
rimethamine are scarce. Despite an extensive search of the
literature, we have been unable to find data related to the
minimum AQ, sulfadoxine, or pyrimethamine concentration in
human blood that is effective in curing a parasite strain sus-
ceptible in vitro to the corresponding drug. However, the day
3 plasma concentrations measured in the present study were in
the same range as those obtained in Cameroon following ad-
ministration of the same drug regimen (30). As in this study,
interindividual variations were high. Interestingly, in our study,
posttreatment MdAQ or SP plasma concentrations correlated
to the treatment issue. In addition, we could determine by
logistic regression optimal blood concentration breakpoints for
MdAQ (135 ng/ml), sulfadoxine (100 g/ml), and py-
rimethamine (175 ng/ml), which best separated adequate re-
sponses from treatment failures. The quite high values of the
FIG. 1. Concentrations of pyrimethamine (Pyr) and sulfadoxine
(Sulf) in plasma of 106 patients treated with sulfadoxine-py-
rimethamine and of MdAQ in plasma of 112 patients treated with AQ
in Gabon, 2000. All measurements were done 3 days after initiation of
treatment. Concentrations of pyrimethamine and MdAQ are indicated
in nanograms/milliliter, and those of sulfadoxine are in micrograms/
milliliter. For each treatment, each group of children is divided ac-
cording to treatment efficacy: adequate clinical and parasitological
response () and therapeutic failure ().
TABLE 5. Results of logistic regressions of ACPR on plasma
concentrations of monodesethylamodiaquine (patients treated
with AQ), sulfadoxine or pyrimethamine (patients treated







( or 135 ng/ml)
4.5 1.7–11.5 0.004
Age —b — 0.05
Sulfadoxine
( or 100 g/ml)
9.8 1.9–50.3 0.009
Glycemia — — 0.06
Pyrimethamine
( or 175 ng/ml)
11.8 2.3–59.9 0.005
Glycemia — — 0.09
a Drug thresholds were determined in order to maximize corresponding odds
ratios (see the text for details). South-East Gabon, 2000.
b —, odds ratios were not computed (quantitative variable).
TABLE 6. Discrimination of therapeutic failures after AQ or SP
administration, due to recrudescent parasites (presence of bands
shared by the two patterns) from reinfections (appearance of new
bands in the second pattern) using genotyping comparison of MSP-1
and MSP-2 molecular patterns of P. falciparum parasites in blood





No. (%) of cases with:
Recrudescence Recrudescence
 reinfection Reinfection
AQ LPF 8 12 2
LCF 8 4 1
Total 16 (46) 16 (46) 3 (8)
SP LPF 4 7 0
LCF 0 1 0
Total 4 (33) 8 (67) 0
a See Materials and Methods for details; southeast Gabon, 2000.











odds ratios (4.5 to 11.8) demonstrate the importance of indi-
vidual metabolism of drug in treatment efficacy.
Treatment failures were studied by molecular analysis of the
MSP-1 and -2 genes to distinguish recrudescences from rein-
fections. Molecular genotyping is a suitable method for this
purpose, since in vitro drug sensitivity data may not be suffi-
cient to predict in vivo failures. Indeed, in vivo and in vitro data
from high-transmission areas may not correlate, especially in
the case of SP (3, 29, 30). The inhibitory concentration values
derived from in vitro tests are the summation of the suscepti-
bility values for the various clonal lines with which the infection
originated, these lines being present in highly variable propor-
tions. Since in areas of intense transmission of malaria, the
majority of infections are due to multiple parasite lines, these
mean values may hide minor clones with which recrudescence
will originate. Furthermore, host immunity certainly plays an
important role in adding its activity to that of the drug. The
identification of molecular markers of resistance in parasite
lines may be a useful alternative to in vitro tests. Currently the
relevance of such markers still needs to be confirmed, in par-
ticular for 4-amino-quinoline compounds (36). In our study,
the amplification of two markers, MSP-1 and MSP-2, was suf-
ficient to distinguish reinfection from recrudescence. Both
markers were useful since, if MSP-2 (the most polymorphic
marker) were tested alone, results would have differed in 10 of
the 47 instances: 9 cases of recrudescence plus reinfection
would have been determined as recrudescences, and 1 case of
recrudescence plus reinfection would have been established as
pure reinfection. The RO33 family of MSP-1 exhibited a lim-
ited polymorphism and did not bring any information. This
family was the least represented in our population of isolates,
and the combination of the four remaining families was
enough to distinguish reinfection from recrudescence. This
may not be the case in areas of low transmission, where most
infections are monoclonal.
In most instances, reappearance of parasites in blood fol-
lowing antimalarial treatment involved both the recrudescence
of parasite clones present before treatment and the appear-
ance of new clone(s) not present at D0. Such an observation
was already reported from Gabon, where pre- and posttreat-
ment samples from 108 children showed either identical par-
asites, a mixture of pretreatment and new parasites, or com-
pletely different parasites (28). This last group, corresponding
to children presenting with a new infection, represented less
than 13% of the whole group. In Papua New Guinea, AQ or
chloroquine failures occurring in 12 children were all due to
recrudescent parasites (2). Although reinfection with a clone
presenting with a molecular profile similar to that of the D0
clone cannot be ruled out, the persistence of clones present at
D0 most likely demonstrates that treatment failed to clear
these parasites and thus demonstrates a true therapeutic fail-
ure. Conversely, although the multiplication of clones not
present before treatment is most likely the consequence of
reinfection, clones were shown to fluctuate in the peripheral
blood with time, suggesting that some of them may have been
hidden in the deep vasculature at D0. This phenomenon was
demonstrated both in a low-transmission area during a several-
month period of absence of transmission (40) and in holoen-
demic areas during a day-to-day study of genotypes (8, 14).
Only three cases of pure reinfection, for which the molecular
pattern of D0 and DF were completely different, were ob-
served. Our method of analysis is likely to overestimate both
recrudescences and reinfections, but this constitutes the limits
of genotyping as an adjunct tool in treatment efficacy studies.
The study of additional genetic polymorphic markers, such as
GLURP, might have allowed the distinguishing of isolates that
did not differ as regards MSP-1 and MSP-2 and would have
even reduced the number of pure reinfections.
One of our objectives was to assess the usefulness of such a
pharmacological and genotypic approach in better measuring
drug efficacy. It is clear that interpretation of drug dosages
requires the knowledge of the effective minimum concentra-
tions of these drugs in blood, which seems to be still unknown.
Before determination of such values, the usefulness of post-
therapeutic drug dosages during field studies remains ques-
tionable at the individual level. From a pharmacokinetics point
of view, the area under the curve better reflects the effective
drug concentration, but such data cannot be collected in a field
study, and low residual values indicate inadequate absorption
and metabolism of the drug. Nevertheless, the importance of
drug absorption and metabolism is demonstrated by the higher
ACPR rate observed in patients with a high posttreatment
concentration of drug in plasma. Among the 47 parasite cures
followed by reappearance of parasites in blood (which were
labeled “therapeutic failures” in the in vivo test), MSP geno-
typing was able to demonstrate that 3 (6.4%) of them were not
the result of treatment inefficacy but only involved new infec-
tion. Therefore, the additional use of these techniques allows
the assessment that therapeutic failures due to parasite resis-
tance to treatment occurred in 32.2% (instead of 34.7%) of
children treated with amodiaquine and in 14.0% (similar
value) of children treated with SP. The use of parasite geno-
typing in addition to in vivo testing allows greater accuracy in
determining the therapeutic efficacy of AQ and SP, but this
gain was only moderate in the epidemiological conditions from
Gabon. This combination of techniques allowed in vitro drug
tests to be avoided in an area of high malaria transmission,
where the complexity of infection is high (4.0 clones) and
where immunity plays an important role, both phenomena
reducing the relationship between in vitro test results and
treatment efficacy. It is clear that in areas of such levels of drug
resistance and such complexity of infections, the interest of
assessing drug levels and parasite genotypes should be
weighted with regard to the needed logistical constraints and
the limited increase in the precision of the measurement of
treatment efficacy. Nevertheless, the levels of resistance to AQ
and the SP combination in this region of southeast Gabon
begin to be alarming, and new antimalarial agents or new
combinations urgently need to be tested and used in order to
reduce the spread of resistance and to avoid the excessive use
of quinine that is very frequent in this area.
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